Anupam Rasayan Q1 FY27 Revenue up 36% YoY to ₹6,675 Mn
Anupam Rasayan India Limited announced its unaudited financial results for the quarter ended June 30, 2026. The company reported a consolidated revenue of ₹6,675 million, a significant 36% year-on-year increase from ₹4,907 million in Q1 FY26. EBITDA also grew by 35% YoY to ₹1,749 million, maintaining a healthy EBITDA margin of 26.2%. Profit After Tax (PAT) for the quarter stood at ₹512 million, a 6% rise from ₹485 million in the prior year's quarter. The company highlighted key achievements including the commercialization of Ethyl Trifluoroacetate using flow chemistry and a Letter of Intent with BASQUEVOLT for a potential US$300 million supply deal over ten years. The proposed acquisition of Bliss GVS Pharma is also progressing as planned.
Key Highlights
- Consolidated revenue surged 36% YoY to ₹6,675 Mn in Q1 FY27.
- EBITDA increased 35% YoY to ₹1,749 Mn, with margins at 26.2%.
- PAT grew 6% YoY to ₹512 Mn.
- Commercialized Ethyl Trifluoroacetate using flow chemistry.
- Signed LOI for potential US$300 Mn supply deal with BASQUEVOLT.
Price Impact
More from ANURAS